Medidata Solutions — Merger or Acquisition (June 2019)
13 slides from Medidata Solutions's merger presentation, Jun 13, 2019
Slide 1: Corporate and conference call participants
all 12588841-2019-06-12T16:07:02.133 C O R P O R A T E P A R T I C I P A N T S Bernard S. Charlès Dassault Systèmes SE - Vice Chairman & CEO François-José Bordonado Dassault Systèmes SE - Vice-President of IR Glen M. de Vries Medidata Solutions, Inc. - Co-Founder, President & Director Pascal Daloz D
Slide 2: Proposed Medidata Solutions Acquisition
Proposed Medidata Solutions Acquisition June 12, 2019 Dassault Systémes and Medidata Solutions to Join Forces To Accelerate the Life Sciences Industry Innovation For Patient-Centric Experience Through End-to-End Collaborative Platform 3DEXPERIENCE” ris cara 2
Slide 3: Forward-looking statements
Forward-looking statements Some of the comments on this presentation contain forward-looking statements, which could differ materially from actual results. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation
Slide 4: Dassault Systemes to Acquire Medidata Solutions
Dassault Systemes to Acquire Medidata Solutions A Purpose Driven Strategic Move 7) fl ? Dassault Systémes provides business & r people with 3DEXPERIENCE universes to ») imagine sustainable innovations capable of J harmonizing product, nature and life. th Re +P] , ;
Slide 5: Our Belief
Our Belief Virtual world extends and improves real world The virtual world will catalyze the next generation of therapeutics
Slide 6: Dassault Systemes Current TAM: $33bn
Dassault Systemes Current TAM*: $33bn Life « y $4bn Tam ?) Nature VPA Product \, a, $25bn tam ©” $4bn tam * TAME Total Addressable Maat a!
Slide 7: Therapeutic Innovation in the Age of Experience
Therapeutic Innovation in the Age of Experience .@ 20 years A oge | Centric Drug Development 10 y
Slide 8: The Opportunity to Improve Patients' Outcomes
The Opportunity to Improve Patients’ Outcomes New Drugs Development Metrics: t) Low success rate <10% from Phase 1 clinical trial testing to regulatory approval * Significant opportunities Long timelines ~10 years to help the life from drug discovery to approval ** sciences industry i and patient ou
Slide 9: Medidata's Product Portfolio
Medidata’s Product Portfolio Transforming clinical development and converting complex data into ~\ - cutting-edge insights > | Ra ACORN AI SHYFT CLINICAL TRIAL Al DRIVEN CLINICAL & DATA CAPTURE & INSIGHTS FOR COMMERCIAL OPERATIONS LIFE SCIENCES INTELLIGENCE
Slide 10: Medidata at a Glance (non-GAAP)
Medidata at a Glance (non-caar) Market Leader indata capture and ~ $7bn TAM* 1,300 clinical trial management solutions customers FY18 revenue: 100% SAAS-based On a comparable basis™, ~ US$ 636m Shee PFE of FY18 em margin: up ~17% ~ 84% revenue ~16% Only of revenue Workforce: Listed company ~24% from
Slide 11: Creating First End-to-End Scientific and Business Platform
Creating First End-to-End Scientific and Business Platform Made to Cure c) oH ° PY Manufacturing —— Commercialization Research & Discovery ton Preclinical development HM 208 stand-alone Medidata Solutions
Slide 12: Transaction Overview (non-IFRS)
Transaction Overview (non-IFRS) Merger agreement signed on June 12" Transaction ll cash one-step merger to be approved by Medidata’s shareholders Enterprise value of $5.8bn Committed financing facility €4 billion debt package with targeted Strong Investment Grade rating Fi i €1 billion term loan and
Slide 13: Important Additional Information and Where to Find It
Important Additional Information and Where to Find It In connection with the proposed merger, Medidata Solutions, Inc. (the “Company”) intends to file relevant materials with the Securities and Exchange Commission (the “SEC”), including a preliminary proxy statement on Schedule 14A. Following the fi
Medidata Solutions — Merger or Acquisition (June 2019) on 6ix